APBMT Annual Report
2020

Asia-Pacific Blood and Marrow Transplantation Group
SECRETARIAT OFFICE / DATA CENTER OF APBMT
Asia-Pacific Blood and Marrow Transplantation Group (APBMT)

Annual Report

2020

Secretariat Office / Data Center of APBMT

E-mail: office@apbmt.org
Website: https://www.apbmt.org
Contents

Introduction
General Overview 2020
Bylaws
Organizational Tree
Principal Member List
Annual Congresses
Number of Attendees for Each Annual Congress

Registry Committee
About Registry Committee
About Activity Survey
About Outcome Registry
Registry Committee Member List

Nuclear Accident Management (NAM) Committee
NAM Committee Activities and Member List

Executive Board
Executive Board Activities
Executive Board Members

Collaboration with Other International Registries
General Information
History of International Scientific Symposia

Blood Cell Therapy -The Official Journal of APBMT-
About the Journal
Editorial Board Member List
List of the Accepted Articles

Appendix
Offering Delta Mileage to Medical Professionals in Emerging Countries
Cooperate Members and Banner Contributions
Introduction
General Overview 2020

All 22 of APBMT’s participating countries/regions are listed here. (As of December 2020)

Australia
Bangladesh
Cambodia
China
Hong Kong
India
Indonesia
Iran
Japan
Korea
Malaysia
Mongolia
Myanmar
Nepal
New Zealand
Pakistan
Philippines
Singapore
Sri Lanka
Taiwan
Thailand
Vietnam

This Annual Report is the 13th edition and the 2nd digital one, which includes APBMT activities from January to December in 2020. Though the COVID-19 pandemic had a powerful influence on the field of HSCT medicine in this region throughout the year, all doctors and allied health professionals made a great effort to care for patients with hematological diseases. The COVID-19 pandemic had also forced us to give up holding the in-person annual congress in India, however, the organizing committee in the Indian Society for Blood and Marrow Transplantation successfully convened our first annual congress on the virtual platform in collaboration with the APBMT Executive Board.

Please note that from this edition, the results of the Activity Survey are separated from the Annual Report. You can find them on the APBMT website: 
https://www.apbmt.org/research/registry/survey
BYLAWS OF THE ASIA PACIFIC BLOOD AND MARROW TRANSPLANTATION GROUP  
(APBMT)

ARTICLE 1

Name of the Group

The Asia Pacific Blood and Marrow Transplantation Group, hereafter referred to as APBMT was established in 1990 to allow doctors, other health professionals and scientists in the Asia Pacific region involved in clinical blood and marrow transplantation and therapies related to hematopoietic stem cell transplantation to collaborate and promote high quality blood and marrow transplantation in the region.

ARTICLE 2

Incorporation

APBMT is incorporated as Corporate Juridical Person for scientific and educational purposes under the laws of Japan.

ARTICLE 3

Purpose of APBMT

The group aims to promote all aspects associated with the hematopoietic stem cell transplantation (HSCT) and related therapies in the Asia Pacific region, which includes:

- To ascertain and provide the updated status of haematopoietic stem cell transplantation (HSCT) in the Asia Pacific region.
- To steer and regulate the HSCT Registry in the Asia Pacific region (Asia Pacific Blood and Marrow Transplantation Group Registry: APBMT Registry)
- To share current knowledge of all aspects of HSCT to promote and maintain the highest standards of care, and to work towards a set of standards and accreditation of transplant units.
- To provide training opportunities in HSCT in the Asia Pacific region.
- To promote collaborative research in the Asia Pacific region.
- To collaborate with other international organizations related with HSCT
- To work as a core voting member of WBMT
ARTICLE 4
Organization

The schema of the organization in APBMT indicates below.

4. Membership Any persons involved in the treatment of recipients and donors (such as physicians, nurses, laboratory technicians, persons related to stem cell donor programs or pharmaceutical companies), who are involved in HSCT and agree with the purpose of the group can become a member (see above section). New members are admitted by submitting a membership application form and CV up to 2 pages to the Secretary Office. This application must include the signature of an APBMT member as a presenter. There are two different kinds of memberships; Scientific members (physicians, nurses, laboratory technicians, persons related to stem cell donor programs) and Corporate members (pharmaceutical and for-profit companies). Scientific members include Regular, Associate, Affiliate, Honorary and Emeritus members. All members have to pay annual membership fees except for the Honorary and Emeritus members.

4.1 Regular members
Regular members consist of members from medical fields with an M.D. or Ph.D sufficient experiences and demonstrated in hematopoietic stem cell transplantation / cellular therapy. A proposed new member must provide a membership application form and CV that includes professional qualification, work experiences, current employment and place of work to the Secretariat Office. Regular members must agree to abide by the regulations of APBMT, to participate in scientific endeavors of APBMT, to have good ethical and moral standards as well as no criminal record, as expected by professional societies. Regular members can attend the Business meeting but do not have voting right. Regular members can elect and can be elected as Scientific Committee members within each country.

4.2 Associate members
Individuals with and M.D. or Ph.D who do not meet the criteria for regular membership will become Associate members. Associate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.3 Affiliate members
Professionals who are members of HSCT / cellular therapy team or interested in HSCT / cellular therapy (NP, PA, Pham D, RN etc.) are eligible to be Affiliate members. Affiliate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.4 Emeritus members
Anyone in APBMT who has contributed in a significant way to its development is eligible to become Emeritus Members. Emeritus members are nominated by the Executive Board and are approved by the Scientific Committee at the business meeting. Emeritus Members are eligible to participate in the business meeting.

4.5 Honorary members
Individuals who are not an APBMT member but have contributed to the establishment or the development of APBMT are eligible to become an Honorary member. Honorary members are nominated by the APBMT members and are approved by the Scientific Committee at the business meeting. Honorary
members are ineligible to participate in the Business meeting.

4.6 Corporate members
Representatives of commercial and for-profit companies can become Corporate members. Corporate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.7 Scientific Committee
Scientific Committee is the supreme decision-making body in APBMT. Each country can elect and nominate 1 voting member as the country representative. The vote is casted by the country representative but this right may be transferred to a designated substitute. If there is more than one nominee from one country, the Scientific Committee can vote to select one candidate. The names of the current members of scientific committee are listed and updated annually. The Chairman of the Executive Board, who also serves as the Chairman of the Scientific Committee, has the deciding vote if the vote is otherwise tied. New Scientific Committee members need to be recommended by the current members of Scientific Committee among the members of the Regular Members and to get approval in the business meeting. Decisions are taken by majority voting (One vote/one country). A proposed new member must provide a brief CV up to 3 pages. The criteria to be a Scientific Committee Member include proven medical and/or scientific experience in HSCT; willingness to committee and participate in scientific endeavors of APBMT; no criminal record, good ethical and moral standards as expected by professional societies. The Scientific Committee member has the following rights and obligations: 1) To attend the Annual Business Meeting; 2) To elect Executive Board members; 3) To decide on admission of new members; 4) To decide the annual fee for APBMT membership; 5) To make final decision on APBMT policies and its finance. A Scientific Committee member will lose his/her rights as a representative of his/her country/region when he/she leaves his/her original country/region permanently.

4.8 Executive Board
The Executive Board of APBMT steers the group for administration and all decisions that need to be taken for functioning of the organization in accordance
with the constitution and bylaws of the organization. The Executive Board is responsible for all running operations and decisions that are not due to be taken by the Scientific Committee at the annual meeting. The Executive Board, appointed by the Scientific Committee, will act on behalf of all members for regular decisions during the period between Scientific Committee meetings. During this period, the Scientific Committee need not be consulted unless a decision would affect the bylaws or contravene a decision previously made by the Scientific Committee. The Executive Board consisted of regular members (only one member permitted from one country) elected from the Scientific Committee. The maximum number of members of the Executive Board is nine. The Chairman of Executive Board represents APBMT.

4.9 Officers of the Executive Board
1. Scientific Committee elects a) one Chairman of Executive Board, b) one Vice Chairman of Executive Board, c) several other Members of Executive Board including one Secretariat / Treasurer. The members of the Executive Board are elected by the business meeting, and serves for two years and may be re-elected for another term of two years.
2. The function of the Chairman of Executive Board is to promote and coordinate all activities of APBMT. These include fund raising, coordination of Working Group activities, giving suggestions to the organizers of the annual meeting, and negotiations with other organizations on behalf of APBMT.
3. The Vice Chairman supports the Chairman and will perform the duties of the Chairman in the absence.

4.10 Secretariat/Treasureer
Secretariat / Treasurer shall oversee the maintenance of a permanent record of APBMT. The Secretariat / Treasurer shall have oversight of the budget of APBMT. The Secretariat / Treasurer Office works for the development and the maintenance of the group under the collaboration with the Chairman of Executive Board, the Chairman of the next annual congress, and the members of Executive Board and Scientific Committee.

ARTICLE 5
Committees and Working Groups
5.1 Committees
APBMT will have the following Standing Committees to help with its work.
1. Membership Committee
2. Registry Committee
3. Program Committee
4. Nuclear Accident Management (NAM) Committee
5. Editorial Board of the Blood Cell Therapy, the Official Journal of APBMT
Each of these committees will have a specific term of reference.

5.2 Working Groups
The aim of Working Groups is to enhance research in focused areas. The Executive Board and Scientific Committee of APBMT determine the formation of Working Groups as required. The application of the new Working Group and its chair person is approved by the members of the Scientific Committee in the Business Meeting (see Annex). The chair person of each Working Group is elected for three years and may stand for reelection once. The substructure of the Working Group is defined by the chair person in consultation with the Executive Board. Regular Members are encouraged to participate in one or more Working Groups according to their particular interests. The Working Group chair person must submit annual activity reports to the Scientific Committee and the Executive Board. The chairperson should adhere to the Working Group responsibilities, which are specified separately from the bylaws.

ARTICLE 6
Meetings
6.1 Annual Congress
Any countries participating in APBMT can propose to be a host country of the Annual Congress. Host country of the future Annual Congresses will be decided by the Scientific Committee. The President of the next annual congress cooperates with the Executive Board for the year preceding the annual congress. The format of the meeting is to be standardized (see Annex section below).

6.2. Business Meeting
The Scientific Committee will open the Business Meeting at least once a year. One of them will be held during the annual meeting. It is co-chaired by the Chairman of the Executive Board and the President of the Annual Congress. The Board may establish subcommittee / working party as the need arises.
6.3 Board Meeting
The Executive Board of the APBMT shall meet in person at the annual meeting. It is presumed that all members will attend this meeting unless there are unavoidable personal circumstances. In addition, the board will meet via conference calls every 4-8 weeks, as needed. All members are expected to attend all scheduled board meetings.

ARTICLE 7
7.1 APBMT Registry
A major activity of the APBMT will be to guide the development of national registries in each country. This data will then be collected into the combined APBMT registry in formats compatible with other international registries. Both activities and outcome data will be collected every year.

7.2 Annual Report
The list of registrants and summary of analyses are published in the APBMT Annual Report of each year, which is distributed to the APBMT member and related persons / organizations. The results published in the APBMT Annual Report is confidential, however, it can be quoted after written approval from APBMT and accompanied by proper acknowledgement.

7.3 Rules on the use of the Registry data
Data are restricted to publication in a scientific article and / or presentation at academic meetings. APBMT contributions must be appropriately acknowledged in all presentations and publications prior to the release of the data and analyses. Written Applications for these purposes are limited to Scientific Committee Members, Working Groups and the Data Center of APBMT for the time being. Written requests from other academic organizations or commercial companies will be assessed and if approved a cost recovery will be charged depending on the amount of work. Confidentiality of source information will be protected in accordance with the laws of individual centres and countries. An application form is attached as a separate sheet. The Registry Committee will evaluate all applications and approval made after consultation with the Executive Board.

ARTICLE 8
Finance

8.1 Membership Fees:
All the Regular Members are required to pay annual membership fees on an individual basis (see Annex). The members who paid the membership fees can receive up-to-date information including the survey data from APBMT office and also may have the advantage of discount of the registration fees at annual congress.

8.2 Statement of accounts of annual APBMT congress
An audited statement of accounts must be prepared by the organizing committee for each annual APBMT meeting within one year of its completion and submitted to the APBMT Headquarters and presented at the annual business meeting.

ARTICLE 9
Amendments
9.1 These Bylaws may be amended at any annual business meeting of the Scientific Committee Amendments to the Bylaws may be proposed in writing to the Executive Board and must be submitted at least ninety days prior to the annual meeting. In addition, the Executive Board may initiate proposed amendments to the Bylaws. The proposed amendments, together with the Executive Board’s recommendation, shall be distributed to members of the Scientific Committee at least thirty days before the annual meeting at which it is to be considered. To be adopted, an amendment must be approved by at least two thirds of voting at the annual meeting.

9.2 Annexures may be amended by the Executive Board, (with a minimum of two third majorities of the members of the Executive Board) and report to the Scientific Committee.

Annexures:
1. Committees - Terms of Reference to be determined.
2. Working Groups - Terms of Reference to be determined.
3. Annual Congress – Format of the meeting to be formulated
4. The APBMT Registry
5. Financial Issues
6. The Scientific Committee members: In addition to the criteria to be a Scientific Committee Member described in APBMT Bylaw (4.7 Scientific Committee), the candidate must have served as a regular member for the past three years with the consecutive payment of annual membership fee. No term limits are set for Scientific Committee Members. However, the members are required to participate in at least 2 out of 4 most recent APBMT Annual Congress, and consecutively pay annual membership fee in order to maintain their membership. In addition, their willingness of serving as Scientific Committee Members is to confirm every two years. No limits are set for the maximum number of Scientific Committee members in each country/region participating APBMT.

7. Others
(Detailed rules such as payments and duties for the members are described in the annexure)

Establishment: October 1, 2009
History of revision:
- December 31, 2010
- October 31, 2015
- November 1, 2016 (Annexure 6 was added.)
- August 31, 2019
Principal Member List

Executive Board members

Shinichiro Okamoto (Chairman, Japan) Alok Srivastava (Vice-chair, India) David D Ma (Australia/New Zealand)
He Huang (China) Amir Ali Hamidieh (Iran) Jong Wook Lee (Korea)
William YK Hwang (Singapore)

Scientific Committee Members (*Executive Board members)

Yoshiki Akatsuka (Japan) Otgonbat Altangerel (Mongolia) Shashikant Apte (India)
Khishigjargal Batsukh (Mongolia) Carmella Bingcang (Philippines) Pheng Bora (Cambodia)
Udomsak Bunworasate (Thailand) Po-Min Chen (Taiwan) Tzeon-Jye Chiou (Taiwan)
Gin Gin Gan (Malaysia) Lallindra Gooneratne (Sri Lanka) Aye Aye Gyi (Myanmar)
Amir Ali Hamidieh (Iran) * Suradej Hongeng (Thailand) He Huang (China) *
Xiao-Jun Huang (China) Tai-ju Hwang (Korea) William YK Hwang (Singapore) *
Hyoung Jin Kang (Korea) Mohiuddin Khan (Bangladesh) Navin Khattry (India)
Bor-Sheng Ko (Taiwan) Mickey Koh (Singapore) Hoon Kook (Korea)
Jong Wook Lee (Korea) * Albert Lie (Hong Kong) Kai-Hsin Lin (Taiwan)
Kai-yan Liu (China) David D Ma (Australia/New Zealand) * Koichi Miyamura (Japan)
Shinichiro Okamoto (Japan) * Jian Ouyang (China) Chi Dung Phu (Vietnam)
Bishesh Sharma Poudyal (Nepal) Damai Santosa (Indonesia) Tahir Sultan Shamsi (Pakistan)
Alok Srivastava (India) * Jih-Luh Tang (Taiwan) Shuichi Taniguchi (Japan)
Takanori Teshima (Japan) Artit Ungkanont (Thailand) Auro Viswabandya (India)
Jianmin Wang (China) Jong-Ho Won (Korea) Tong Wu (China)
Ming Yao (Taiwan) Mei Zhang (China)

Honorary Members

Kerry Atkinson (Australia) John Carter (New Zealand) Dennis Confer (NMDP)
John Goldman (EBMT) Alois Gratwohl (EBMT) Geoffrey Hill (Australia)
Mary Horowitz (CIBMTR) Dietger Niederwieser (EBMT)

Emeritus Members

Suresh H Advani (India) Shigetaka Asano (Japan) Lu Xian Cao (China)
Ardeshir Ghavamzadeh (Iran) Surapol Issaragrisil (Thailand) Saengseree Jootar (Thailand)
Chun Choo Kim (Korea) Dong Jip Kim (Korea) Yoshihisa Kodera (Japan)
Dao-Pei Lu (China) Tohru Masaoka (Japan) Tan Binh Nguyen (Vietnam)
Philip Rowlings (Australia/New Zealand) Tapan K Saikia (India) Patric Tan (Singapore)
Annual Congresses of APBMT

Previous Congresses

<table>
<thead>
<tr>
<th>No</th>
<th>Year</th>
<th>City</th>
<th>Presidents</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>1990</td>
<td>Beijing</td>
<td>Lu Xian Cao</td>
</tr>
<tr>
<td>2nd</td>
<td>1991</td>
<td>Nagoya</td>
<td>Tohru Masaoka</td>
</tr>
<tr>
<td>3rd</td>
<td>1992</td>
<td>Osaka</td>
<td>Tohru Masaoka</td>
</tr>
<tr>
<td>4th</td>
<td>1994</td>
<td>Fukuoka</td>
<td>Tohru Masaoka</td>
</tr>
<tr>
<td>5th</td>
<td>1996</td>
<td>Seoul</td>
<td>Dong Jip Kim</td>
</tr>
<tr>
<td>6th</td>
<td>1998</td>
<td>Taipei</td>
<td>Yao-Chang Chen</td>
</tr>
<tr>
<td>7th</td>
<td>2000</td>
<td>Bangkok</td>
<td>Surapol Issaragrisil</td>
</tr>
<tr>
<td>8th</td>
<td>2002</td>
<td>Mumbai</td>
<td>Suresh Advani</td>
</tr>
<tr>
<td>9th</td>
<td>2004</td>
<td>Tehran</td>
<td>Ardeshr Ghavamzadeh</td>
</tr>
<tr>
<td>10th</td>
<td>2005</td>
<td>Hangzhou</td>
<td>Dao-Pei Lu</td>
</tr>
<tr>
<td>11th</td>
<td>2006</td>
<td>Nagoya</td>
<td>Yoshihisa Kodera</td>
</tr>
<tr>
<td>12th</td>
<td>2007</td>
<td>Beijing</td>
<td>Dao-Pei Lu</td>
</tr>
<tr>
<td>13th</td>
<td>2008</td>
<td>Taipei</td>
<td>Po-Min Chen</td>
</tr>
<tr>
<td>14th</td>
<td>2009</td>
<td>Seoul</td>
<td>Chun-Choo Kim</td>
</tr>
<tr>
<td>15th</td>
<td>2010</td>
<td>Phuket</td>
<td>Saengsuree Jootar</td>
</tr>
<tr>
<td>16th</td>
<td>2011</td>
<td>Sydney</td>
<td>David Ma / Philip Rowlings</td>
</tr>
<tr>
<td>17th</td>
<td>2012</td>
<td>Hyderabad</td>
<td>Tapan K Saikia / Alok Srivastava</td>
</tr>
<tr>
<td>18th</td>
<td>2013</td>
<td>Ho Chi Minh City</td>
<td>Tan Binh Nguyen</td>
</tr>
<tr>
<td>19th</td>
<td>2014</td>
<td>Hangzhou</td>
<td>He Huang / Xiaojun Huang</td>
</tr>
<tr>
<td>20th</td>
<td>2015</td>
<td>Okinawa</td>
<td>Shinichiro Okamoto</td>
</tr>
<tr>
<td>21st</td>
<td>2016</td>
<td>Singapore</td>
<td>William YK Hwang / Chng Wee Joo / Aloysius Ho</td>
</tr>
<tr>
<td>22nd</td>
<td>2017</td>
<td>Tehran</td>
<td>Ardeshr Ghavamzadeh</td>
</tr>
<tr>
<td>23rd</td>
<td>2018</td>
<td>Taipei</td>
<td>Ming Yao / Jih-Luh Tang</td>
</tr>
<tr>
<td>24th</td>
<td>2019</td>
<td>Busan</td>
<td>Jong Wook Lee / Jong-Ho Won</td>
</tr>
<tr>
<td>25th</td>
<td>2020</td>
<td>APBMT/ISBMT (Virtual)</td>
<td>Mammen Chandy</td>
</tr>
</tbody>
</table>

As of May 18, 2021
Future Congresses

- The 26th Annual Congress (Hybrid)
  15-17 of October 2021, Chang Mai, Thailand
  Congress President: Artit Ungkanont
  Scientific Chair: Suradej Hongeng
  Scientific co-Chair: Udmsak Bunworasate

- The 27th Annual Congress will be hosted by Indian Society for Blood and Marrow Transplantation (ISBMT) in 2022
### The Number of Attendees for Each Annual Congress from 2009 to 2020

<table>
<thead>
<tr>
<th>2009(KOREA)</th>
<th>2010(THAILAND)</th>
<th>2011(AUSTRALIA/New Zealand)</th>
<th>2012(INDIA)</th>
<th>2013(VIETNAM)</th>
<th>2014(CHINA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Korea</td>
<td>292</td>
<td>Thailand</td>
<td>280</td>
<td>Australia</td>
<td>637</td>
</tr>
<tr>
<td>China</td>
<td>65</td>
<td>China</td>
<td>100</td>
<td>China</td>
<td>178</td>
</tr>
<tr>
<td>Taiwan</td>
<td>34</td>
<td>Taiwan</td>
<td>63</td>
<td>New Zealand</td>
<td>84</td>
</tr>
<tr>
<td>Japan</td>
<td>33</td>
<td>Korea</td>
<td>52</td>
<td>Korea</td>
<td>57</td>
</tr>
<tr>
<td>Thailand</td>
<td>19</td>
<td>Japan</td>
<td>25</td>
<td>Vietnam</td>
<td>38</td>
</tr>
<tr>
<td>Australia</td>
<td>7</td>
<td>Singapore</td>
<td>19</td>
<td>Singapore</td>
<td>16</td>
</tr>
<tr>
<td>Viet Nam</td>
<td>5</td>
<td>Malaysia</td>
<td>17</td>
<td>Malaysia</td>
<td>14</td>
</tr>
<tr>
<td>USA</td>
<td>4</td>
<td>Hong Kong</td>
<td>13</td>
<td>Singapore</td>
<td>14</td>
</tr>
<tr>
<td>Germany</td>
<td>3</td>
<td>Vietnam</td>
<td>13</td>
<td>Thailand</td>
<td>12</td>
</tr>
<tr>
<td>Singapore</td>
<td>2</td>
<td>Australia</td>
<td>9</td>
<td>Vietnam</td>
<td>10</td>
</tr>
<tr>
<td>France</td>
<td>1</td>
<td>Iran</td>
<td>8</td>
<td>Philippines</td>
<td>9</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>1</td>
<td>Italy</td>
<td>6</td>
<td>India</td>
<td>6</td>
</tr>
<tr>
<td>Indonesia</td>
<td>1</td>
<td>Germany</td>
<td>4</td>
<td>Hong Kong</td>
<td>5</td>
</tr>
<tr>
<td>Iran</td>
<td>1</td>
<td>Indonesia</td>
<td>4</td>
<td>Myanmar</td>
<td>4</td>
</tr>
<tr>
<td>Malaysia</td>
<td>1</td>
<td>USA</td>
<td>4</td>
<td>Switzerland</td>
<td>3</td>
</tr>
<tr>
<td>Philippines</td>
<td>1</td>
<td>India</td>
<td>3</td>
<td>Bangladesh</td>
<td>3</td>
</tr>
<tr>
<td>Switzerland</td>
<td>1</td>
<td>Pakistan</td>
<td>3</td>
<td>Pakistan</td>
<td>3</td>
</tr>
<tr>
<td>UK</td>
<td>1</td>
<td>France</td>
<td>2</td>
<td>Fiji</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>472</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Domestic</td>
<td>62</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foreign</td>
<td>38</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>633</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>%</td>
<td>%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Domestic</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foreign</td>
<td>56</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1115</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

As of May 18, 2021

*ASIA-PACIFIC BLOOD AND MARROW TRANSPLANTATION GROUP*
<table>
<thead>
<tr>
<th>2015(JAPAN)</th>
<th>2016(SINGAPORE)</th>
<th>2017(IRAN)</th>
<th>2018(TAIWAN)</th>
<th>2019(KOREA)</th>
<th>2020(APBMT/ISBMT (Virtual))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Japan</td>
<td>159</td>
<td>Singapore</td>
<td>234</td>
<td>565</td>
<td>Taiwan</td>
</tr>
<tr>
<td>China</td>
<td>186</td>
<td>China</td>
<td>116</td>
<td>32</td>
<td>China</td>
</tr>
<tr>
<td>Taiwan</td>
<td>51</td>
<td>Japan</td>
<td>62</td>
<td>4</td>
<td>Japan</td>
</tr>
<tr>
<td>Korea</td>
<td>41</td>
<td>Korea</td>
<td>44</td>
<td>4</td>
<td>Korea</td>
</tr>
<tr>
<td>Singapore</td>
<td>23</td>
<td>Taiwan</td>
<td>28</td>
<td>3</td>
<td>Singapore</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>17</td>
<td>India</td>
<td>25</td>
<td>3</td>
<td>Vietnam</td>
</tr>
<tr>
<td>Vietnam</td>
<td>16</td>
<td>USA</td>
<td>22</td>
<td>3</td>
<td>Thailand</td>
</tr>
<tr>
<td>India</td>
<td>11</td>
<td>Thailand</td>
<td>21</td>
<td>2</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Thailand</td>
<td>11</td>
<td>Hong Kong</td>
<td>19</td>
<td>2</td>
<td>USA</td>
</tr>
<tr>
<td>Indonesia</td>
<td>9</td>
<td>Malaysia</td>
<td>19</td>
<td>1</td>
<td>Belgium</td>
</tr>
<tr>
<td>USA</td>
<td>7</td>
<td>Malaysia</td>
<td>15</td>
<td>1</td>
<td>India</td>
</tr>
<tr>
<td>Malaysia</td>
<td>6</td>
<td>Vietnam</td>
<td>15</td>
<td>1</td>
<td>Turkey</td>
</tr>
<tr>
<td>Australia</td>
<td>5</td>
<td>Australia</td>
<td>13</td>
<td>1</td>
<td>UK</td>
</tr>
<tr>
<td>Philippines</td>
<td>5</td>
<td>Philippines</td>
<td>11</td>
<td>1</td>
<td>Malaysia</td>
</tr>
<tr>
<td>UK</td>
<td>4</td>
<td>Philippines</td>
<td>10</td>
<td>1</td>
<td>Malaysia</td>
</tr>
<tr>
<td>Germany</td>
<td>2</td>
<td>Philippines</td>
<td>9</td>
<td>1</td>
<td>Switzerland</td>
</tr>
<tr>
<td>England</td>
<td>2</td>
<td>Sri Lanka</td>
<td>6</td>
<td>1</td>
<td>Total</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>1</td>
<td>France</td>
<td>4</td>
<td>1</td>
<td>Domest</td>
</tr>
<tr>
<td>Cambodia</td>
<td>1</td>
<td>Mongolia</td>
<td>4</td>
<td>1</td>
<td>Foreign</td>
</tr>
<tr>
<td>Canada</td>
<td>1</td>
<td>Indonesia</td>
<td>3</td>
<td>1</td>
<td>Myanmar</td>
</tr>
<tr>
<td>France</td>
<td>1</td>
<td>Ireland</td>
<td>3</td>
<td>2</td>
<td>Romania</td>
</tr>
<tr>
<td>Italy</td>
<td>1</td>
<td>Italy</td>
<td>3</td>
<td>1</td>
<td>Cambodia</td>
</tr>
<tr>
<td>Mongolia</td>
<td>1</td>
<td>Cambodia</td>
<td>2</td>
<td>1</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Myanmar</td>
<td>1</td>
<td>Myanmar</td>
<td>2</td>
<td>1</td>
<td>Iran</td>
</tr>
<tr>
<td>Pakistan</td>
<td>1</td>
<td>Qatar</td>
<td>2</td>
<td>1</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Switzerland</td>
<td>1</td>
<td>Belgium</td>
<td>1</td>
<td>1</td>
<td>North Korea</td>
</tr>
<tr>
<td>Missing</td>
<td>1</td>
<td>Canada</td>
<td>1</td>
<td>1</td>
<td>Spain</td>
</tr>
<tr>
<td>Total</td>
<td>567</td>
<td>Nepal</td>
<td>1</td>
<td>1</td>
<td>Total</td>
</tr>
</tbody>
</table>

| Domestic | 28 | Spain | 1 | Domestic | 46 | Myanmar | 1 | Netherlands | 1 |
| Foreign  | 72 | Switzerland | 1 | Foreign | 54 | Nepal | 1 | United Arab Emirates | 1 |

| Total    | 1206 | Domestic | 53 | Foreign | 47 |

Domestic: 63
Foreign: 37

Asia-Pacific Blood and Marrow Transplantation Group

As of May 18, 2021
Registry Committee
APBMT Registry Committee

APBMT has long collected HSCT activity and outcome data through APBMT Data Center. To promote and accelerate the data collection, APBMT decided to establish the Registry Committee in October 2014 and it officially started operations in October 2015. APBMT Data Center was integrated into the committee. The Registry Committee members are basically nominated among the APBMT members in each country/region and have a web conference every two months.

Since the committee has launched the work, four important official documents have been finalized.

- Protocol
- Letter of Commitment
- Informed Consent for Patients
- Detailed Rules for Data Usage and Authorship
  (Revised version 2.0 was approved on July 16, 2020)

Based on these documents, committee members work hard:

- To perform APBMT Activity Survey and Outcome Registry annually
- To support data collection in participating countries/regions
- To manage and analyze the collected data
- To optimize the data usage
- To support clinical researches using collected data

[About Activity Survey]
The APBMT Activity Survey has been performed annually from 2007 (HSCT data from 2005). This survey is a collection of the number of transplantations sorted by the donor sources and diseases in each country/region.

The following figure shows how the data is collected.
The method of submission is different in each country/region.
As shown in the Figure above, data from China, India, Japan, Korea, Malaysia, and Taiwan was submitted through their respective national registry. The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) submitted the national data for Australia and New Zealand. In Bangladesh, Iran, Myanmar, the Philippines, Sri Lanka, and Thailand data was collected by a designated contact person and submitted to Data Center. Data Center has direct contact with major transplantation centers and receives data from Hong Kong, Indonesia, Mongolia, Nepal, Pakistan, Singapore, and Vietnam. Data Center compiles all data collected in each of these 7 countries/regions, and compiled data is available for each country/region to use as national data.

The results of the Activity Survey are put on the APBMT website: https://www.apbmt.org/research/registry/survey

A new paper was submitted from the Registry Committee in 2020:
APBMT Registry Committee and Data Center have been collecting the HSCT outcome data of each patient. The basic dataset structure is called the Least Minimum Dataset (LMD) and three methods are available for sending data to Data Center depending on the situation in each country/region.

- The simplified Excel forms made by APBMT Data Center based on the EBMT MED-A or the CIBMTR TED
- Receiving data from CIBMTR through data transfer agreements, which were established between APBMT and CIBMTR and between APBMT and some centers that submitted Outcome Data to CIBMTR
- The electronic data capture (EDC) system using REDCap®

When the Registry/Society in participating counties/regions starts to submit HSCT outcome data to APBMT, a Non-Disclosure Agreement (NDA) is signed between APBMT and the Registry/Society when requested. In addition, APBMT Registry Committee stipulates detailed rules for data usage so that the submitted data will not be disclosed without the consent of the Committee.

*The following countries/regions are building up their systems for submitting outcome data: Indonesia, Iran, Korea, Malaysia, and Thailand
# Registry Committee Member List

<table>
<thead>
<tr>
<th>Name</th>
<th>Country/Region</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chairperson</strong></td>
<td></td>
</tr>
<tr>
<td>Yoshiko Atsuta</td>
<td>Japan</td>
</tr>
<tr>
<td><strong>Deputy Chairpersons</strong></td>
<td></td>
</tr>
<tr>
<td>Anthony Dodds</td>
<td>Australia/New Zealand</td>
</tr>
<tr>
<td>Aloysius Ho</td>
<td>Singapore</td>
</tr>
<tr>
<td><strong>Members</strong></td>
<td></td>
</tr>
<tr>
<td>Mafruhah Akter</td>
<td>Bangladesh</td>
</tr>
<tr>
<td>Pheng Bora</td>
<td>Cambodia</td>
</tr>
<tr>
<td>Xiao Jun Huang</td>
<td>China</td>
</tr>
<tr>
<td>Liu Kaiyan</td>
<td>China</td>
</tr>
<tr>
<td>Joycelyn Sim</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Alok Srivastava</td>
<td>India</td>
</tr>
<tr>
<td>Kavitha M.L</td>
<td>India</td>
</tr>
<tr>
<td>Damai Santosa</td>
<td>Indonesia</td>
</tr>
<tr>
<td>Amir Hamidieh</td>
<td>Iran</td>
</tr>
<tr>
<td>Shinichiro Okamoto</td>
<td>Japan</td>
</tr>
<tr>
<td>Yachiyo Kuwatsuka</td>
<td>Japan</td>
</tr>
<tr>
<td>Joon Ho Moon</td>
<td>Korea</td>
</tr>
<tr>
<td>Kim Wah Ho</td>
<td>Malaysia</td>
</tr>
<tr>
<td>Batsukh Khishigjargal</td>
<td>Mongolia</td>
</tr>
<tr>
<td>Aye Aye Gyi</td>
<td>Myanmar</td>
</tr>
<tr>
<td>Tasneem Farzana</td>
<td>Pakistan</td>
</tr>
<tr>
<td>Marjorie Rose Bravo</td>
<td>Philippines</td>
</tr>
<tr>
<td>Prasad Abeysinghe</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>Devinda Jayathilake</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>Bor-Sheng Ko</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Hui-Fen Chiang</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Po-Nan Wang</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Ming Yao</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Artit Ungkanont</td>
<td>Thailand</td>
</tr>
<tr>
<td>Huynh Van Man</td>
<td>Vietnam</td>
</tr>
<tr>
<td><strong>Data Center</strong></td>
<td></td>
</tr>
<tr>
<td>Minako Iida</td>
<td>Japan</td>
</tr>
<tr>
<td>Yukari Nakao</td>
<td>Japan</td>
</tr>
<tr>
<td>Hiroe Namizaki</td>
<td>Japan</td>
</tr>
</tbody>
</table>
Nuclear Accident Management (NAM) Committee
Nuclear Accident Management (NAM) Committee

The APBMT Nuclear Accident Management Committee (NAM Committee) was established at the APBMT Annual Congress in Hyderabad, India in 2012 to:

1) investigate what is happening in this region and what is being done around the world in the field of a nuclear accident
2) facilitate cooperation with other societies such as EBMT, ASTCT, and WBMT
3) establish an APBMT Nuclear Accident Registry
4) establish a training program
5) prepare the standard operating procedure for the handling of Nuclear accident in our region

Since then, the NAM meeting has been held every year at the Annual Congress and the final draft of the NAM guidelines, written by co-chairs (Drs. Velu Nair and Hyo Rak Lee), was approved by the APBMT Scientific Committee.

https://www.apbmt.org/education/guideline-nam

### Member list

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Country/Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Velu Nair</td>
<td>India</td>
</tr>
<tr>
<td>Chair</td>
<td>Hyo Rak Lee</td>
<td>Korea</td>
</tr>
<tr>
<td>Past Chair</td>
<td>Alok Srivastava</td>
<td>India</td>
</tr>
<tr>
<td>Past Chair</td>
<td>David Ma</td>
<td>Australia</td>
</tr>
<tr>
<td></td>
<td>Mohiuddin Khan</td>
<td>Bangladesh</td>
</tr>
<tr>
<td></td>
<td>Koichi Miyamura</td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td>Syuuichi Taniguchi</td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td>Khishigjargal Batsukh</td>
<td>Mongolia</td>
</tr>
<tr>
<td></td>
<td>Aye Aye Gyi</td>
<td>Myanmar</td>
</tr>
<tr>
<td></td>
<td>Simit Sapkota</td>
<td>Nepal</td>
</tr>
<tr>
<td></td>
<td>Prasad Abeysinghe</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td></td>
<td>Phu Chi Dung</td>
<td>Vietnam</td>
</tr>
<tr>
<td>Chairman, Executive Board</td>
<td>Shinichiro Okamoto</td>
<td>Japan</td>
</tr>
</tbody>
</table>
Executive Board
Executive Board Activities

For smooth management of the international society, Executive Board members have official web conferences every month as well as ad-hoc web conferences as needed. The main topics discussed in the Executive Board web conferences are:

- Working together with local organizing committees to prepare for each annual congress
  - Making up the scientific program
  - Nomination of speakers
- An office-centered organizational approach of hosting the annual congress
- Nominating the host country for the upcoming annual congress
- Amendment of the Bylaws and membership definition
- Rulemaking for each committee
- Sponsorship contract with the third parties/companies
- Education/training of physicians/nurses involved in HSCT and cell therapy
- Collaboration with ASTCT, EBMT, WBMT, and other related societies in the field of HSCT
  - Nomination of speakers for the Joint Sessions in each annual congress
  - Nomination of representatives to societies which requested
- Membership control
  - Review of membership application forms
  - Membership fees
  - Dual membership between ASTCT
- Solving the problems with advice to each committee (Registry Committee, Editorial Board of Blood Cell Therapy, Financial Committee)
Executive Board Members

Shinichiro Okamoto
Chairman
Japan

Alok Srivastava
Vice Chairman
India

Jong-Wook Lee
Korea

David Ma
Australia

Amir Hamidieh
Iran

William Hwang
Singapore

He Huang
China
Collaboration with Other International Registries

WBMT
ASTCT
EBMT
**WBMT (Worldwide Network for Blood & Marrow Transplantation)**

APBMT is one of the first founding societies of WBMT and has collaborated with other member societies such as CIBMTR, EBMT, and WMDA to operate WBMT since 2007.

Dr. Yoshihisa Kodera (Japan) and Dr. Jeff Szer (Australia) have served as the WBMT president, and many members in APBMT played important roles in the Standing Committees in 2020: Co-chair of Education & Dissemination Committee: Yoshihisa Kodera, Co-chair of Global Emergencies/Nuclear Accident Management Committee: David Ma, Co-chair of Transplant Centre/Recipient Committee: Yoshiko Atsuta.

In addition, APBMT Data Center has submitted the Activity Survey data every year to contribute to the WBMT Global Transplant Activity Survey.

**ASTCT (American Society for Transplantation and Cellular Therapy)**

After exchanging memorandums of understanding for dual membership on August 23, 2018, APBMT and ASTCT implemented the dual membership, and APBMT members who applied for this membership could receive many benefits from ASTCT. APBMT and ASTCT will continue to proceed with the second and third collaboration projects.

**EBMT (European Society for Blood and Marrow Transplantation)**

With the cooperation of EBMT, APBMT could set up an original booth at the annual meeting for the past few years. APBMT could exhibit the activities and contact with not only registered members but also non-members there. With regard to a project for the establishment of the APBMT Center Standards, we could get informative advice from JACIE members.
History of International Scientific Symposia

2020

May, WBMT Live Webinar (Online)
COVID-19 and stem cell transplantation, a Worldwide perspective:
Moderators: Y Kodera, MD; S Galeano, MD
- Management of donors during the pandemic (F. Alfraih)
- Transplant recipients; COVID-19 guidelines and real-world (C. Machado)
- Chinese experience (H. Huang)
- Data from the EBMT registry during COVID-19 (P. Ljungman)
- Chimeric Antigen Receptor T Cell Therapy during COVID-19 (MA Perales)

2019

August, APBMT (Korea)
ASTCT/EBMT/WBMT/APBMT Joint Session:
Co-Chairs: JW Lee, MD; S. Okamoto, MD
- GvHD Prophylaxis with Post Cy after Haplo-Identical, Matched Unrelated and HLA-Identical Sibling Transplantation (N. Kroger)
- Future Changes in Stem Cell Transplantation and Cellular Therapy: Safer, Less Toxic and Less Costly Approaches (D. Weisdorf)
- Novel Approaches for Treating and Preventing GvHD (JF DiPersio)
- Design the Future of Hematopoietic Cell Transplantation (HCT) in Asia-Pacific Countries/Regions (S. Okamoto)

2018

November, APBMT (Taiwan)
ASBMT / EBMT / WBMT / APBMT Joint Symposium: Past, Now, and Future of Hematopoietic Stem Cell Transplantation
Co-Chairs: M. Yao, MD; S. Okamoto, MD
- Hematopoietic Stem Cell Transplantation: Where we have come from and where do we go? (J. Gajewski)
- Past, now and future of hematopoietic stem cell transplantation (EBMT prospective) (N. Kroger)
- How does the past predict the future of allogeneic transplantation: lessons for the field? (D. Weisdorf)
- How the APBMT is facing the challenge (S. Okamoto)

September, The 5th WBMT Workshop (Beijing, China)
International Experience and Data Sharing to Improve Access and Outcomes of
Transplantation

1. Importance of creating the HSCT global outcome registration system
   - Global perspective of HSCT & registration (J Szer)
   - WBMT Global Survey & registration (D Niederwieser)
   - CIBMTR perspective of HSCT and registration (M Pasquini)
   - HSC Donor Registries: Challenges and Perspectives (C Muller)
   - APBMT perspective: Importance of Outcome Data Sharing in Asian Pacific Region (Y Kodera)
   - Current Activity Survey in the AP region (M Iida)
   - Outcome Registry Current Status and future perspectives (Y Atsuta)
   - Chinese perspective of HSCT and Activity Surveys; Difficulties in Data collection (X Huang)

2. International Standards and Accreditation
   - Steps towards international accreditation: Lessons learned (S Okamoto)
   - Addressing unproven cellular therapies (M Koh)

April, WBMT/AfBMT (Morocco)
First Meeting of the African Blood and Marrow Transplantation Group: SCT in bone marrow failure
Co-Chairs: N. Novitzky, MD; N. Khoubila, MD
   - Recent Progress in Diagnosis and Treatment of Inherited Bone Marrow Failure (S. Kojima)
   - Acquired (S. Osman Ahmed)

October, APBMT (Iran)
APBMT / WBMT Joint Session: Transplantation reports in the Asian Pacific region & the progress of BMT in the world and Asian Pacific region
Co-Chairs: A. Ghavamzadeh, MD; S. Okamoto, MD
   - The progress of BMT in the Islamic Republic of Iran (A. Ghavamzadeh)
   - The report of transplantation in all 15 BMT centers of Iran in the last five years (A. Hajifathali)
   - The current status and future challenges of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) (S. Okamoto)
   - The history, current status and future trends of WBMT (Y. Kodera)
   - The report of transplantation in China five recent years (H. Huang)
   - The advance of HSCT after the enforcement of “The Act for Appropriate Provision of Hematopoietic Stem Cells to be Used in Transplantations” in Japan (Y. Kodera)
Outcome of autologous hematopoietic stem cell transplants for multiple myeloma in a single center in Sri Lanka (L. Gooneratne)
The report of transplantation in Malaysia in five recent years (OT. Chuan)

2016

**October, APBMT (Singapore)**

*WBMT Programme- ASBMT/EBMT/APBMT Joint Session*
Co-Chairs: Y. Kodera, MD; J. Szer, MD
- Future of Hematopoietic Stem Cell Transplantation & Cellular Therapy
  Modern Conditioning Regimens Prior to allo – HSCT (M. Mohty)
- Hematopoietic Cell Transplant Activity in the United States (CN. Bredeson)
- Design the Future of Hematopoietic Stem Cell Transplantation: APBMT Perspectives (S. Okamoto)
- WBMT – Who Are We, What Have We Done and What Will We Do? (J. Szer)

**February, BMT Tandem Meetings**

*Stem Cell Transplantation for Bone Marrow Failure*
Co-Chairs: S. Kojima, MD; SA. Giralt, MD
- Hematopoietic Stem Cell Transplantation in Adult Patients with Acquired Aplastic Anemia: Asian Perspectives (JW. Lee)
- Bone Marrow Failure in Children (S. Kojima)
- Poor Graft Function Post-Transplant – Time to Take this Seriously (SA. Giralt)

2015

**October, APBMT (Japan)**

*Global Trend of HSCT and the Future Role of APBMT (WBMT/APBMT Joint Session (II))*
Co-Chairs: Y. Kodera, MD; S. Okamoto, MD
- Medical Products of Human Origin WHO Project: Regulatory Recommendations for MPHO-WBMT (JR. Nunez)
- Global Trends in Hematopoietic Stem Cell Transplantation (HSCT) (D. Niederwieser)
- Starting New HSCT Program in Emerging Countries in Asia-Pacific Area (D. Ma)

*Working together with Emerging Countries in HSCT in Asia (WBMT/APBMT Joint Session (II))*
Co-Chairs: TK. Saikia, MD; AA. Hamidieh, MD
- Report from Mongolia (B. Khishigjargal)
Report from Sri Lanka (L. Gooneratne)
Report from Myanmar (AA. Gyi)
Report from Indonesia (H. Hariman)
Report from Philippines (HG. Baylon)
Report from Bangladesh (MA. Khan)
Report from Cambodia (B. Pheng)

Future in Hematopoietic Stem Cell Transplantation (ASBMT/EBMT/APBMT Joint Session)
Co-Chairs: S. Okamoto, MD; W. Hwang, MD
- Hematopoietic Cell Transplantation in 2015: How the ASBMT is Facing the Challenges (C. Bredeson)
- Challenges in Hematopoietic Stem Cell Transplantation: The EBMT Perspective (M. Mohty)
- Future of Hematopoietic Stem Cell Transplantation – Asia Pacific perspective (A. Srivastava)

Global Alliance for Nuclear Accident Management in the Field of Hematopoietic Stem Cell Transplantation
Co-Chairs: D. Ma, MD; Y. Kodera, MD
- The Current Status of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) in the Management of Nuclear Accident (D. Ma)
- The Contribution of EBMT to the Global Response of a Large Number of Radiation Victims (R. Pawles)
- Radiation Injury Treatment Network: Hematologists and Oncologists Preparing for a Radiological Disaster (C. Case)

March, EBMT
Innovations in Cancer: A Joint EBMT-EHA-APBMT Session
Co-Chairs: M. Mohty, MD; C. Chomienne, MD; AA. Hamidieh, MD
- New drugs in hematology (M. Mohty)
- Leukemic stem cell heterogeneity: how to monitor and eradicate (C. Chomienne)
- Pediatric HSCT: challenges in the Asia-pacific region (AA. Hamidieh)
Blood Cell Therapy is the official journal of Asia-Pacific Blood and Marrow Transplantation Group. We have published it since October 2018 and issue quarterly.

Online ISSN: 2432-7026
Journal homepage: https://bct.apbmt.org/

Aims and scope: Blood Cell Therapy is an international journal publishing peer-reviewed original and review articles in the field of all aspects of hematopoietic cell transplantation and cell therapy. Not only clinical research but also basic research relevant to cell therapy are covered. The scope of our journal encompasses wide variety of clinical or basic topics including:

- Results of trials with new protocols
- Transplant-related complications
- Transplant outcome studies dealing with QOL, psychology, economy or regional characteristics
- Prognostic analysis based on biomarkers
- Translational research
- Transplantation immunology
- Cellular or gene therapy
# Editorial Board Member List

<table>
<thead>
<tr>
<th>Name</th>
<th>Commission</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yoshiki Akatsuka</td>
<td>Editor-in-Chief</td>
<td>Japan</td>
</tr>
<tr>
<td>Tatsuo Ichinohe</td>
<td>Deputy Editor-in-Chief</td>
<td>Japan</td>
</tr>
<tr>
<td>Shinichiro Okamoto</td>
<td>Chairman of APBMT</td>
<td>Japan</td>
</tr>
<tr>
<td>Jeffrey Szer</td>
<td>Associate Editors</td>
<td>Australia</td>
</tr>
<tr>
<td>Haowen Xiao</td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Navin Khattry</td>
<td></td>
<td>India</td>
</tr>
<tr>
<td>Auro Viswabandya</td>
<td></td>
<td>India</td>
</tr>
<tr>
<td>Ayami Yoshimi</td>
<td></td>
<td>Germany / Japan</td>
</tr>
<tr>
<td>Satoshi Takahashi</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Junya Kanda</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Seok-Goo Cho</td>
<td></td>
<td>Korea</td>
</tr>
<tr>
<td>Jae Yong Kwak</td>
<td></td>
<td>Korea</td>
</tr>
<tr>
<td>Hee-Je Kim</td>
<td></td>
<td>Korea</td>
</tr>
<tr>
<td>Mickey Boon Chai Koh</td>
<td></td>
<td>Singapore</td>
</tr>
<tr>
<td>David Yeung</td>
<td></td>
<td>Australia</td>
</tr>
<tr>
<td>Mei Zhang</td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Yuqian Sun</td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Alok Srivastava</td>
<td></td>
<td>India</td>
</tr>
<tr>
<td>Amir Hamidieh</td>
<td></td>
<td>Iran</td>
</tr>
<tr>
<td>Maryam Behfar</td>
<td></td>
<td>Iran</td>
</tr>
<tr>
<td>Akio Kohno</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Mahmoud Aljurf</td>
<td></td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td>Daniel Weisdorf</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Minako Iida</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Yukari Nakao</td>
<td>Editorial Office</td>
<td>Japan</td>
</tr>
<tr>
<td>Hiroe Namizaki</td>
<td></td>
<td>Japan</td>
</tr>
</tbody>
</table>

*random order

# Information for Submission

Manuscript submission rules for Authors: [https://bct.apbmt.org/for_authors/](https://bct.apbmt.org/for_authors/)
Editorial Policies: [https://bct.apbmt.org/editorial_policies/](https://bct.apbmt.org/editorial_policies/)
Guide for Reviewers: [https://bct.apbmt.org/for_reviewers/](https://bct.apbmt.org/for_reviewers/)
Submission: [https://mc.manuscriptcentral.com/bct](https://mc.manuscriptcentral.com/bct)
List of the Accepted Articles (As of December 31, 2019)

**Original Article**

**Monitoring of citrulline and diamine oxidase levels as biomarkers for intestinal mucositis during early-phase hematopoietic cell transplantation**

Noriyasu Fukushima1,2,3, Satoshi Tomiyasu2, Yoshinori Uji2, Masako Yokoo2, Takero Shindo3, Yasushi Kubota3, Toshihiko Ando3, Kensuke Kojima3, Eisaburo Sueoka4, Tatsuo Ichinohe1, Shinya Kimura3

1Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. 2Department of Medical Science Technology, School of Health Sciences at Fukuoka, International University of Health and Welfare, Okawa, Japan. 3Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan. 4Department of Laboratory Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Blood Cell Therapy Vol.1 Issue.1 No.1 Pages 1-8

Submitted: December 19, 2017  Accepted: July 7, 2018  Published online: August 29, 2018

DOI:https://doi.org/10.31547/bct-2017-002

**Review Article**

**Recent advances and current challenges in allogeneic stem cell transplantation in patients with acquired severe aplastic anemia**

Sung-Eun Lee and Jong Wook Lee

Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Blood Cell Therapy Vol.1 Issue.1 No.2 Pages 9-17

Submitted: March 6, 2018  Accepted: May 19, 2018  Published online: August 29, 2018

DOI:https://doi.org/10.31547/bct-2018-001

**Review Article**

**Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy**

Yingying Yang, Yongxian Hu, Jiasheng Wang, He Huang

Zhejiang University School of Medicine First Affiliated Hospital

Blood Cell Therapy Vol.1 Issue.1 No.3 Pages 18-27

Submitted: April 12, 2018  Accepted: July 7, 2018  Published online: August 29, 2018

DOI:https://doi.org/10.31547/bct-2018-003
Case Report
Primary CNS post-transplant lymphoproliferative disorder following haploidentical HSCT using post-transplant high-dose cyclophosphamide
Masako Toyosaki, Makoto Onizuka, Jun Amaki, Sawako Shiraiwa, Yasuyuki Aoyama, Shinichiro Machida, Hidetsugu Kawai, Hiromichi Murayama, Daisuke Ogiya, Keiko Matsuji, Shohei Kawakami, Kaito Harada, Yusuke Kondo, Kenichi Hirabayashi, Naoya Nakamura, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando
1Division of Hematology and Oncology, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan, 2Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan
Blood Cell Therapy Vol.2 Issue.1 No.1 Pages 1-4
Submitted: May 8, 2018   Accepted: August 9, 2018   Published online: October 26, 2018
DOI:https://doi.org/10.31547/bct-2018-004

Case Report
Successful allogeneic peripheral blood stem cell transplantation for an aggressive variant of T-cell large granular-lymphocyte leukemia: A case report
Kazuhito Suzuki, Kaichi Nishiwaki, Jiro Minami, Hidekazu Masuoka, Mitsuji Katori, Hiroki Yokoyama, Hideki Uryu, Shingo Yanoz
1Division of Clinical Oncology/Hematology, The Jikei University Kashigaoka Hospital, 2Division of Clinical Oncology/Hematology, The Jikei University School of Medicine
Blood Cell Therapy Vol.2 Issue.1 No.2 Pages 5-8
Submitted: May 20, 2018   Accepted: September 5, 2018   Published online: October 26, 2018
DOI:https://doi.org/10.31547/bct-2018-006

Case Report
Gastric antral vascular ectasia in a pediatric patient with neuroblastoma who underwent tandem stem cell transplantation
Yumiko Sugishita, Shohei Yamamoto, Ryota Kaneko, Naoko Okamoto, Masaya Koganesawa, Sachio Fujita, Kosuke Akiyama, Ryosuke Matsuno, Daisuke Toyama, Keiichi Isoyama
Department of Pediatrics, Showa University Fujigaoka Hospital, Japan
Blood Cell Therapy Vol.2 Issue.1 No.3 Pages 9-11
Submitted: August 24, 2018   Accepted: October 2, 2018   Published online: January 15, 2019
DOI:https://doi.org/10.31547/bct-2018-007
**Review Article**

**Autologous hematopoietic stem cell transplant for autoimmune diseases: evolution, evidence of efficacy, and real-world economics**

Massey, Jennifer C.1,2,3, Moore, John J.2,3,4, Milliken, Samuel T.4, Ma, David D. F.2,3,4,5

1Department of Neurology, St Vincent’s Hospital Sydney, Australia, 2Blood, Stem Cell and Cancer Research Program, St Vincent’s Centre for Applied Medical Research, Sydney, Australia, 3St Vincent’s Clinical School, Faculty of Medicine, University of NSW, Sydney, Australia, 4Department of Haematology and Bone Marrow Transplant, St Vincent’s Hospital Sydney, Australia, 5Corresponding author

Blood Cell Therapy Vol.2 Issue.2 No.1 Pages 12-21

Submitted: September 14, 2018  Accepted: October 23, 2018  Published online: April 1, 2019

DOI:https://doi.org/10.31547/bct-2018-009

**Original Article**

**Kinetics of neutrophil engraftment in allogeneic stem cell transplantation**

Akihisa Kawajiri1, Shigeo Fuji1,2, Yoshihiro Inamoto1, Saiko Kurosawa1, Takashi Tanaka1, Ayumu Ito1, Keiji Okinaka1, Sung-Won Kim1, Takahiro Fukuda1

1Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
2Department of Hematology, Osaka International Cancer Institute, Osaka, Japan

Blood Cell Therapy Vol.2 Issue.2 No.2 Pages 22-30

Submitted: October 20, 2018  Accepted: January 23, 2019  Published online: April 1, 2019

DOI:https://doi.org/10.31547/bct-2018-011

**Short Communication**

**A decade of excellent transplant survival in children with inherited metabolic diseases: A report from a single metabolic transplant centre in Europe**

Su Han Lum1, Andrew Will1, Heather J Church1, Jean Mercer2, Karen L Tylee1, Kay Poulton1, Wendy Ogens1, Helena Lees1, Alison Logan1, Mary Coussons3, Tasneem Khalids3, Denise Bonney3, Stewart Rusts3, Prashant Hiwarkar3, Simon A Jones3, Robert F Wynn1

1Department of Pediatric Blood and Marrow Transplant, Royal Manchester Children’s Hospital, UK, 2Manchester Center for Genomic Medicine, St Mary’s Hospital, Manchester, UK, 3Transplantation Laboratory, Manchester Royal Infirmary, Manchester, UK, 4Therapeutic Stem Cell Laboratory, Royal Manchester Children’s Hospital, Manchester, UK, 5Department of Pharmacy, Royal Manchester Children’s Hospital, Manchester, UK, 6Pediatric Psychosocial Department, Royal Manchester Children’s Hospital, Manchester, UK

Blood Cell Therapy Vol.2 Issue.2 No.3 Pages 31-35

Submitted: October 23, 2018  Accepted: February 8, 2019  Published online: May 10, 2019

DOI:https://doi.org/10.31547/bct-2018-012
**Case Report**

Role of hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a report of 2 unique cases

Yadanar Lwin, David Ma

Department of Haematology and BM Transplant, St Vincent’s Hospital Sydney, NSW, Australia, St Vincent’s Clinical School, Faculty of Medicine, the University of New South Wales

Blood Cell Therapy Vol.2 Issue.3 No.1 Pages 36-38

Submitted: March 25, 2019  Accepted: April 5, 2019  Published online: June 7, 2019

DOI:https://doi.org/10.31547/bct-2019-001

**Original Article**

Predictors of parental distress during acute phase of pediatric hematopoietic stem cell transplantation in Japan: A multicenter prospective study

Shohei Nakajima, Ami Setoyama, Iori Sato, Tomoko Fukushima, Harumi Tanaka, Masami Inoue, Kentaro Watanabe, Katsuyoshi Koh, Junko Takitas, Mika Tokuyama, Kenichiro Watanabe, Kiyoko Kamibeppu

Department of Family Nursing, Division of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Nursing, Osaka Women’s and Children’s Hospital, Osaka, Japan, Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, Osaka, Japan, Department of Hematology/Oncology, Saitama Children’s Medical Center, Saitama, Japan, Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan, Department of Hematology and Oncology, Shizuoka Children’s Hospital, Shizuoka, Japan.

Blood Cell Therapy Vol.2 Issue.3 No.2 Pages 39-49

Submitted: October 18, 2018  Accepted: April 15, 2019  Published online: June 18, 2019

DOI:https://doi.org/10.31547/bct-2018-010
**Survey Report**

**Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka**

P Abeysinghe, L Morawaka, S Gunasekara, S Suress, PWDCC Jayathilake, PHSP Udara, PPR Siriwardena, S Milliken, J Moore, DDF Ma

1National Cancer Institute, Sri Lanka, 2National Blood Transfusion Service, Sri Lanka, 3Department of Haematology and BM Transplantation, St. Vincent’s Hospital Sydney, NSW, Australia

Blood Cell Therapy Volume 2 Issue 4 No.1 Pages 50-53

Submitted: May 29, 2019  Accepted: August 25, 2019  Published online: November 25, 2019

DOI:https://doi.org/10.31547/bct-2019-007

**Survey Report**

**Transplant Programs in APBMT: Blood and Marrow Transplant Activity Report from Myanmar APBMT Meeting 2018, Taiwan**

Aye Aye Gyi, Htun Lwin Nyein, Thida Aung, Rai Mra

1Department of Clinical Haematology, North Okkalapa General and Teaching Hospital, University of Medicine 2, Yangon, Myanmar, 2Department of Clinical Haematology, Yangon General Hospital, Yangon, 3National Blood Center, Yangon, 4Myanmar Society of Haematology, Myanmar Medical Association


Submitted: June 18, 2019  Accepted: September 9, 2019  Published online: November 25, 2019

DOI:https://doi.org/10.31547/bct-2019-008

**Review Article**

**Expansion of Haematopoietic Stem and Progenitor Cells: Paving the Way for Next-Generation Haematopoietic Stem Cell Transplantation**

Sudipto Bari, Paul Chong, William Ying Khee Hwang

1National Cancer Centre Singapore, 2Department of Haematology, Singapore General Hospital, Singapore, 3Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore


Submitted: March 29, 2019  Accepted: September 18, 2019  Published online: November 25, 2019

DOI:https://doi.org/10.31547/bct-2019-004
Survey Report

Autologous stem cell transplant program in 2016–country report from Bangladesh

Mafruha Akter1, Mohiuddin Ahmed Khan, Bimalangshu R Dey2
1BMT Unit, Department of Hematology, Dhaka Medical College Hospital (DMCH), 2Massachusetts General Hospital (MGH), Harvard Medical School, Boston, USA

Blood Cell Therapy Volume 3 (2020) Issue 1 No.1 Pages 1-5
Submitted: May 27, 2019  Accepted: November 18, 2019  Published online: February 25, 2020
DOI: https://doi.org/10.31547/bct-2019-006

Case Report

Successful treatment strategy in incorporating mogamulizumab and cord blood transplantation in aggressive adult T-cell leukemia-lymphoma: a case report

Keiichi Nakata1, Shigeo Fuji1, Midori Koike1, Yuma Tada1, Hiroaki Masaie1, Hitoshi Yoshida1, Eri Watanabe2, Seiichiro Kobayashi1, Arinobu Tojo3, Kaoru Uchimaru3, Jun Ishikawa4
1Department of Hematology, Osaka International Cancer Institute, Osaka, Japan, 2Department of IMSUT Clinical Flow Cytometry Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 3Division of Molecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 4Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Blood Cell Therapy Volume 3 (2020) Issue 1 No.2 Pages 6-10
Submitted: August 27, 2019  Accepted: December 5, 2019  Published online: February 25, 2020
DOI: https://doi.org/10.31547/bct-2019-012

Original Article

Late mortality and causes of death among long-term survivors after autologous hematopoietic stem cell transplantation

Minako Iida1, Hideki Nakasonoe1, Takuya Yamashita1, Masami Inoue2, Yasushi Ishida1, Hitoji Uchiyama1, Yuta Katayama1, Toshihiro Miyamoto1, Satoshi Yoshio1, Souichirou Morita1, Masashi Sawa1, Yasuhiro Sugio1, Takahiro Fukuda4, Tatsuo Ichinohe1, Yoshiho Atsuta1, Yoshihiro Inamot2, for the Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation
1Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan, 2Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 3Department of Hematology, St. Luke's International Hospital, Tokyo, Japan, 4Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan, 5Department of Pediatrics, Ehime Prefectural Central Hospital, Matsuyama, Japan, 6Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 7Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan, 8Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 9Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan,
Blood Cell Therapy Volume 3 (2020) Issue 1 No.3 Pages 11-17
Submitted:October 18, 2018  Accepted:December 14, 2019  Published online:February 25, 2020
DOI:https://doi.org/10.31547/bct-2019-011
**Case Report**

Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure

Hiroshi Imanaga, Takanori Ohta, Seido Oku, Yasuhiro Sugio, Yuju Ohno

1 Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 2 Department of Internal Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan

Blood Cell Therapy Volume 3 (2020) Issue 2 No.1 Pages 18-21

Submitted: July 19, 2019  Accepted: December 15, 2019  Published online: April 21, 2020

DOI: https://doi.org/10.31547/bct-2019-009

**Original Article**

Treatment of relapsed acute leukemia by Ara C plus donor lymphocyte infusion using CD34+ cells reserved at the time of allogeneic transplantation

Lee YJ, Back DW, Cho HC, Moon JH, Sohn SK

1 Division of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea, 2 School of Medicine, Kyungpook National University, Daegu, Republic of Korea

Blood Cell Therapy Volume 3 (2020) Issue 2 No.2 Pages 22-31

Submitted: October 2, 2019  Accepted: December 24, 2019  Published online: April 21, 2020

DOI: https://doi.org/10.31547/bct-2019-015

**Short Communication**

Real-world outcomes of stem cell transplantation for severe aplastic anemia: A single-center experience in Northern India

Dharma Choudhury, Meet Kumar, Sanjeev Sharma, Vipin Khandelwal, Divya Doval, Tina Dadu, Rasika Setia, Anil Handoo

1 Department of Hematology and BMT, BLK Super Specialty Hospital, New Delhi, 2 Department of Hematology, BLK Super Specialty Hospital, New Delhi, 3 Department of Transfusion Medicine, Super Specialty Hospital, New Delhi

Blood Cell Therapy Volume 3 (2020) Issue 2 No.3 Pages 32-36

Submitted: December 16, 2019  Accepted: January 31, 2020  Published online: May 25, 2020

DOI: https://doi.org/10.31547/bct-2019-018

**Review Article**

Hematopoietic Stem Cell Transplantation, Where Have We Come and Where Do We Go

James Gajewski

Hebei Yanda Lu Daopei Hospital (consultant), China

Blood Cell Therapy Volume 3 (2020) Issue 3 No.1 Pages 37-43
Case Report
Post-HSCT relapsed precursor B-cell ALL successfully salvaged by BiTE followed by consolidation CAR-T cell therapy: A report of two cases
Wei-Han Huang1,5,6,7, Chun-Rong Tong2, Tong Wu3, Yun-Chu Lin4, Chi-Cheng Li5,6,7
1Department of Clinical Pathology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, 2Department of Hematology, Beijing Boren Hospital, Beijing, China, 3Department of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, China, 4Department of Hematologic Oncology, National Taiwan University Cancer Center, Taipei, Taiwan, 5Department of Hematology & Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, 6Center of Stem Cell and Precision Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, 7School of Medicine, Tzu Chi University, Hualien, Taiwan

Case Report
Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody
Maria Regina Pelobello de Leon1,2, Shuichiro Takahashi1,3, Masahiro Onozawa1, Makoto Ito4, Manabu Nakano5, Hajime Senjo1, Masahiro Chiba1, Hiroyuki Ohigashi1, Emi Yokoyama1, Junichi Sugita1, Daigo Hashimoto1, Takanori Teshima1
1Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan, 2Department of Medicine, Section of Hematology, Makati Medical Center, Makati City, Phillippines, 3Sapporo Hokuyu Hospital, Sapporo, Japan, 4Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan, 5Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan

Original Article
A Novel Hematopoietic Progenitor Cell Mobilization Regimen Comprising Bortezomib, G-CSF, and Preemptive Plerixafor for Multiple Myeloma
Kazuki Tanimoto, Keiji Sakamoto, Ichiro Kawano, Ikumi Yamanaka, Hideho Henzan
Original Article

Day 0 bone marrow pathology of allogeneic hematopoietic stem cell transplantation is a novel prognostic factor in myeloid malignancies

Takahiko Sato, Naomi Kawashima, Masafumi Ito, Yoshiko Atsuta, Yusuke Kagaya, Aika Seto, Takanobu Morishita, Nobuaki Fukushima, Yukiyasu Ozawa, Koichi Miyamura

Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

Blood Cell Therapy Volume 3 (2020) Issue 4 No.4 Pages 84-91
Submitted:June 6, 2020   Accepted:August 9, 2020   Published online:October 16, 2020
DOI:https://doi.org/10.31547/bct-2020-007
Appendix
Offering Delta Mileage to Medical Professionals in Emerging Countries/Regions to Support their Journeys in the Asia-Pacific Region by the Japanese Marrow Donor Registry Promotion Conference (JMDRPC)

[Background and aims of this project]
APBMT encourages medical professionals in emerging countries/regions to obtain knowledge and skills regarding Hematopoietic Stem Cell Transplantation by attending international congresses which will further contribute to the development of such technologies in their countries. However, costly travel expenses are an obstacle that prevents young medical professionals from participating.
The Japanese Marrow Donor Registry Promotion Conference (JMDRPC) possesses miles donated by contributors who use Delta Airlines through the Sky Wish Charity program. The aim of this project is to utilize these miles to support the travel expenses of medical professionals from emerging countries towards the improvement of hematopoietic cell transplantation; thus, this project will expand opportunities for patients in emerging countries to receive transplants.

[Targets of this support must]
- Have a medical license (doctors, nurses, etc.)
- Have been confirmed to attend a conference related to HSCT in the Asia-Pacific region.
- Be judged as adequate recipients by the judging board of this project

[About the ticket offer]
- Economy class round-trip ticket that is in the service of Delta Airlines and affiliated airlines (Appendix: Sky team alliance)
- It is possible to travel to major cities in the world, though a transit airport might be designated. In addition, departure (in the case of return flights) might be from a domestic hub airport rather than a local airport.
- Fuel surcharge fees and airport usage fees other than the air ticket shall be borne by the applicant (the traveler himself/herself). After determining the flight number/amount, fees are paid to the account of the Japanese Marrow Donor Registry Promotion Conference (JMDRPC).
- Due to the limited number of mileage tickets available, the number of days between flights might increase to more than the traveler originally considered.
[How to apply]
- The applicant must be from an APBMT participating country/region.
- Applicants must complete the application form on the web.

Requirements:
1. Name, occupation, institution, copy of passport
2. Schedule of outbound flight; departure date, departure airport, arrival airport
3. Schedule of return flight; departure date, departure airport, arrival airport

[Responsibility to report]
- Applicants who receive benefits through support from this project are required to submit a small report to APBMT within one month after returning.
- An overview of the report will be included in the publications of the Japanese Marrow Donor Registry Promotion Conference (JMDRPC) and APBMT (Annual Report).

[Contact]
Minako Iida, Yukari Nakao (APBMT Secretariat Office)
Department of Promotion for Blood and Marrow Transplantation
Aichi Medical University, School of Medicine
1-1, Yazakokarimata, Nagakute, Aichi, 480-1195, Japan
Tel: +81-561-62-3311 (Ext.12375)  Fax: +81-561-61-3180
Email address: miida@aichi-med-u.ac.jp

SkyTeam member airlines
Aeroflot Mandarin Airlines KLM Cityhopper
Aerolineas Argentinas China Eastern Airlines KOREAN AIR
Austral Lineas Aereas Shanghai Aielines Jin Air
Aeromexico China Southern Airlines Middle East Airlines
Aeromexico Connect Czech Airlines Saudia
Air Europa Delta Air Lines TAROM
Air France Delta Connection, Delta Shuttle Vietnam Airlines
Alitalia Garuda Indonesia XiamenAir
Alitalia CityLiner Kenya Airways
China Airlines KLM
## Beneficiaries in 2018 and 2019

<table>
<thead>
<tr>
<th>Year</th>
<th>Country</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Malaysia</td>
<td>Bee Ping Chong</td>
</tr>
<tr>
<td></td>
<td>Mongolia</td>
<td>Batsukh Khishigjargal</td>
</tr>
<tr>
<td></td>
<td>Myanmar</td>
<td>Aye Aye Gyi</td>
</tr>
<tr>
<td>2019</td>
<td>India</td>
<td>Uday Yanamandra</td>
</tr>
<tr>
<td></td>
<td>Malaysia</td>
<td>Nur Adila bt Anuar</td>
</tr>
<tr>
<td></td>
<td>Mongolia</td>
<td>Myadagsuren Sukhbaatar</td>
</tr>
<tr>
<td></td>
<td>Malaysia</td>
<td>Norashikin binti Saidon</td>
</tr>
<tr>
<td></td>
<td>Malaysia</td>
<td>Normala binti Arshad</td>
</tr>
<tr>
<td></td>
<td>Malaysia</td>
<td>Zulaili yunus</td>
</tr>
</tbody>
</table>
Cooperate Members

Jazz Pharmaceuticals

Astellas

Japanese Marrow Donor Registry Promotion Conference

JMDRPC

Banner Contributions

MSD

Otsuka
APBMT Annual Report 2020

APBMT officers

President
Shinichio Okamoto
Department of Medicine
Keio University School of Medicine
35 Shinnomachi, Shinjuku, Tokyo, 160-8582, Japan
Tel: +81 3 3335 1221
okamoto.a7@keio.jp

Secretariat office
E-mail: office@apbmt.org
Website: http://www.apbmt.org
Department of Promotion for Blood and Marrow Transplantation
Aichi Medical University School of Medicine
1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan
Tel: +81 561 62 3311 (Ext. 12375) Fax: +81 561 61 3180

Minako Iida
miida@aichi-med-u.ac.jp

Yukari Nakao
yukari-nakao@aichi-med-u.ac.jp

Hiroe Namizaki
namizaki@aichi-med-u.ac.jp